Proactive Investors - Run By Investors For Investors

VolitionRx boosts cash reserves in 1Q

VolitionRx ended its first-quarter with $16.2 million in cash and cash equivalents
lab tech
Volition's NuQ diagnostic blood tests pinpoints irregular levels of nucleosomes in the blood, which indicate cancer

VolitionRx Limited (NYSE AMERICAN:VNRX) on Wednesday announced that it ended its first quarter with $16.2 million in cash and cash equivalents, growing its cash reserves. 

The life-sciences company noted that it had $13.4 million in cash and cash equivalents at the end of 2018. In addition, VolitionRx said it continues to manage cash carefully with a cash burn of $3.9 million in the first quarter, which ended March 31.

WATCH: VolitionRx well positioned as it enters Q2 after strengthening balance sheet

"During the first quarter 2019, we further strengthened our balance sheet with existing investors exercising $6.7 million in aggregate amount of outstanding warrants to purchase shares of our common stock,” said CEO Cameron Reynolds.

He added that “subsequent to the ending of the quarter, a further $5 million in warrants were exercised for cash, making a total of $11.7 million in warrants exercised this year."

The company has designed routine Nu.Q blood-based diagnostic tests to screen for colorectal and prostate cancers that reduce the need for more invasive colonoscopies and biopsies.

VolitionRx’s stock rose 2.15% Wednesday to close at $3.33 a share.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

View full VNRX profile View Profile

VolitionRx Timeline

Related Articles

1550834286_shutterstock_651647128.jpg
February 22 2019
The company is developing drugs for blood disorders, metabolic diseases and curbing alcohol use
A woman with severe depression
April 25 2019
The New York clinical-stage biopharmaceutical company has several drugs in the pipeline capable of generating hefty revenue
cannabis
February 27 2019
The company is a leader for dried flower vaporizers, and a pioneer in cannabis telemedicine and AI technologies
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use